Skin Changes

Coincident inhibition of EGFR signalling predominantly in basal keratinocytes leads to cutaneous adverse events. Only adverse reactions of the skin secondary to EGFRI treatment are addressed in this section. Patients usually experience mild to moderate symptoms that tend to improve during treatment, yet in some cases severe adverse events and progression of skin toxicities are reported. The typical changes seen during EGFRI treatment are: